Table_3_Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001)... by Rafaella F. Q. Grenfell (12841457)

“…Cellular immune response measurement pointed out a mixed immune profile with a robust release of chemokines, cytokines, and growth factors on the first month after CoronaVac vaccination followed by a gradual reduction over time and no increase after the booster dose. …”

Table_2_Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001)... by Rafaella F. Q. Grenfell (12841457)

“…Cellular immune response measurement pointed out a mixed immune profile with a robust release of chemokines, cytokines, and growth factors on the first month after CoronaVac vaccination followed by a gradual reduction over time and no increase after the booster dose. …”

Table_4_Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001)... by Rafaella F. Q. Grenfell (12841457)

“…Cellular immune response measurement pointed out a mixed immune profile with a robust release of chemokines, cytokines, and growth factors on the first month after CoronaVac vaccination followed by a gradual reduction over time and no increase after the booster dose. …”

Table_1_Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001)... by Rafaella F. Q. Grenfell (12841457)

“…Cellular immune response measurement pointed out a mixed immune profile with a robust release of chemokines, cytokines, and growth factors on the first month after CoronaVac vaccination followed by a gradual reduction over time and no increase after the booster dose. …”

Macroscopic current recordings from L1 muscle cells show that thymol is an inhibitor of L-AChR and UNC-49 receptor. by Guillermina Hernando (553795)

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…Mean outpatient visits in the recurrence group decreased from 13.6 ± 3.0 to 11.9 ± 5.0, 8.1 ± 3.9, and 7.8 ± 3.2 at 1, 2, and 3 years postoperatively, respectively (Kruskal-Wallis test, p < 0.001). …”

Spinocerebellar ataxia type 11-associated alleles of <i>Ttbk2</i> dominantly interfere with ciliogenesis and cilium stability by Emily Bowie (543704)

Effects of DMSO on chromosome alignment and spindle organization of <i>in vitro</i> matured porcine oocytes. by Xuan Li (137217)

Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean CRT (μm ± standard deviation) significantly decreased from 504.7 ± 118.2 μm preoperatively to 302.5 ± 60.5 at 1 month, 307.5 ± 64.4 at 3 months, 286.8 ± 49.0 at 6 months, 305.3 ± 79.5 at 12 months, 288.8 ± 79.1 at 24 months, and 295.2 ± 87.4 at 36 months (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Discovery of In Vivo Active Sphingosine-1-phosphate Transporter (Spns2) Inhibitors by Russell Fritzemeier (5538416)

“…Sphingosine 1-phosphate (S1P) is a pleiotropic signaling molecule that interacts with five G-protein-coupled receptors (S1P1-5) to regulate cellular signaling pathways. …”

S2 File - by Ekaterina Khristenko (17847064)

“…It was found more frequently in males (42 out of 56; 75%) than in females (37 out of 61; 60.6%). Additionally, we observed a decrease in muscle mass (hidden sarcopenia) in 79.7% in patients with a normal BMI. …”

S1 File - by Ekaterina Khristenko (17847064)

“…It was found more frequently in males (42 out of 56; 75%) than in females (37 out of 61; 60.6%). Additionally, we observed a decrease in muscle mass (hidden sarcopenia) in 79.7% in patients with a normal BMI. …”

JQ1 increases insulin secretion, content and gene expression in pancreatic β-cells. by Jude T. Deeney (335344)

Microarray gene analysis of BET protein specific siRNA treated INS-1 cells. by Jude T. Deeney (335344)

Dual effect of Algerian propolis on lung cancer: antitumor and chemopreventive effects involving antioxidant activity by Hadjer Brihoum (5383178)

“…A histological analysis further supported these findings and showed a decrease in the number of side effects. …”

Epithelial stem cell engulfment of an apoptotic extracellular vesicle. by Safia A. Essien (20108379)

CsrA modulates the expression of a thiamine pyrophosphate (TPP) riboswitch element. by Tobias Sahr (3756775)

“…<b>B</b>) EMSA with 200nM of biotinylated thi-element (TPP) RNA and purified CsrA: Lane 1: no CsrA, lane 2: 1.0 μM CsrA, lane 3: 2.0 μM CsrA, lane 4: 5.0 μM CsrA, lane 5: 5.0 μM CsrA + 2.0 μM unlabeled RsmZ. …”

hTERT⁺-transfected human lung epithelial A549 cells upregulate FLIP levels and acquire resistance to Fas induced apoptosis. by Nissim Arish (736264)

“…(B) Histogram plots of flow cytometry analysis showing decreased Annexin V staining in hTERT⁺ (red) when compared to hTERT^ctrl (black) transfected cells (A549). …”

Treatment with 1,8-cineole reduced infection and cerebral edema in a model of experimental cerebral malaria. by Edgleyson C. dos Santos (12536575)

Virion-packaged A3G and infectivity of endogenous viruses produced from activated CD4+ T lymphocytes <i>ex vivo</i>. by MariaPia De Pasquale (471291)

“…<p>(<b>A</b>) Increased virion-packaged A3G protein was associated with decreased infectivity of endogenous viruses produced from activated CD4+ T lymphocytes. …”